Welcome to our dedicated page for Arrowhead Pharma news (Ticker: ARWR), a resource for investors and traders seeking the latest updates and insights on Arrowhead Pharma stock.
Arrowhead Pharmaceuticals Inc. (ARWR) is a clinical-stage biotechnology leader developing RNA interference (RNAi) therapies that target disease-causing genes. This page provides investors and industry professionals with verified updates on the company's progress in advancing treatments for genetic disorders through its proprietary TRIM™ delivery platform.
Access consolidated, factual reporting of Arrowhead's material developments including clinical trial milestones, regulatory submissions, research collaborations, and financial disclosures. Our news aggregation ensures efficient tracking of therapeutic advancements in hepatitis B, cardiovascular diseases, and rare genetic conditions.
All content undergoes strict verification to maintain compliance with financial reporting standards. For stakeholders monitoring RNAi innovation and precision medicine breakthroughs, this resource offers centralized access to essential updates without speculative commentary.
Bookmark this page for streamlined monitoring of Arrowhead's progress in developing targeted gene silencing therapies. Check regularly for authoritative reporting on pipeline developments and strategic initiatives shaping the future of RNA-based medicine.
Arrowhead Pharmaceuticals (NASDAQ: ARWR) announced positive interim results from the Phase 1b AROHIF21001 trial for ARO-HIF2, targeting clear cell renal cell carcinoma (ccRCC). The study showed a significant reduction in HIF2α expression, with 9 out of 14 patients demonstrating decreased protein levels. In terms of safety, ARO-HIF2 was well-tolerated, with 12% of patients reporting anemia and hypoxia. The data, presented at the 2022 ASCO GU symposium, highlighted a 39% disease control rate across all cohorts, underscoring the potential of ARO-HIF2 as a therapeutic option in ccRCC.
Arrowhead Pharmaceuticals (NASDAQ: ARWR) reported its financial results for Q1 2022, ending December 31, 2021. The company generated $27.4 million in revenue, an increase from $21.3 million in Q1 2021. However, operating expenses surged to $90.8 million, resulting in a net loss of $62.9 million or $0.60 per share. The company initiated the PALISADE Phase 3 study for ARO-APOC3, advanced two new candidates for pulmonary conditions, and secured a land deal for a new manufacturing facility in Wisconsin. A licensing agreement with GlaxoSmithKline for ARO-HSD was also established.
Arrowhead Pharmaceuticals (NASDAQ: ARWR) announced the closure of its exclusive license agreement with GlaxoSmithKline (LSE/NYSE: GSK), initially revealed on November 22, 2021. The transaction's closing was contingent upon meeting customary closing conditions, including the expiration of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act. This milestone marks a significant step in Arrowhead's collaboration with GSK, potentially impacting its product development and market position.
Arrowhead Pharmaceuticals (NASDAQ: ARWR) will hold a webcast and conference call on February 2, 2022, at 4:30 p.m. ET to discuss its financial results for the first quarter of fiscal 2022, ending December 31, 2021. Interested investors can access the live audio on the company’s website. A replay will be available afterward for 90 days. Arrowhead focuses on developing RNAi-based therapeutics, targeting diseases by silencing specific genes through its innovative RNA chemistries and delivery methods.
Arrowhead Pharmaceuticals (NASDAQ: ARWR) has initiated the Phase 3 PALISADE study to evaluate the efficacy and safety of ARO-APOC3 in patients with familial chylomicronemia syndrome (FCS). ARO-APOC3, an RNA interference therapeutic, aims to inhibit apolipoprotein C3 production, critical for triglyceride metabolism. The study will involve approximately 60 participants and assess changes in triglyceride levels over 56 weeks. Previous studies indicated a significant triglyceride reduction of up to 91%. The company is also collaborating with Ambry Genetics for genetic testing for at-risk patients.
Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) has acquired 13 acres in Verona Technology Park, Wisconsin, where it plans to build a drug manufacturing facility (140,000 sq. ft.) and a laboratory/office space (115,000 sq. ft.). The investment, estimated between $200 million and $250 million, aims to create about 250 jobs. Construction is set to begin in Q1 2022, with lab completion expected in Q1 2023 and manufacturing in Q4 2023. This expansion underscores Arrowhead’s commitment to the Wisconsin biotech ecosystem and supports its growing pipeline of RNAi medicines.
Arrowhead Pharmaceuticals (NASDAQ: ARWR) announced the approval of inducement grants for 24 new employees by its Compensation Committee on December 14, 2021. The grants, totaling up to 87,000 restricted stock units, are meant to incentivize employment and are outside the company’s stockholder-approved equity incentive plans. These units will vest annually over four years, reflecting the company's commitment to attracting talent in its mission to develop innovative RNA interference therapies for intractable diseases.
Arrowhead Pharmaceuticals (NASDAQ: ARWR) announced its participation in two upcoming industry events. On December 2, 2021, Chris Anzalone, Ph.D., president and CEO, will engage in a fireside chat at the 4th Annual Evercore ISI HealthCONx Conference at 1:00 p.m. ET. Following this, December 3, 2021, James Hamilton, MD, MBA, will partake in a panel discussion at the 18th Global Cardiovascular Clinical Trialists Forum, focused on Hypertriglyceridemia Trials. Presentation materials and live webcasts will be available on the company's website.
Arrowhead Pharmaceuticals (NASDAQ: ARWR) reported a revenue of $138.3 million for the fiscal year ending September 30, 2021, up from $88.0 million in 2020. Net loss increased to $140.8 million, or $1.36 per diluted share, compared to $84.6 million, or $0.84 per share, last year. Operating expenses rose significantly to $287.3 million, led by R&D costs of $206.3 million. Cash and cash equivalents totaled $184.4 million, with total assets at $710.1 million. The company also announced a collaboration with GSK for ARO-HSD and received Breakthrough Therapy designation for ARO-AAT.
Arrowhead Pharmaceuticals (NASDAQ: ARWR) has finalized an exclusive license agreement with GlaxoSmithKline (LSE/NYSE: GSK) for ARO-HSD, a therapeutic for nonalcoholic steatohepatitis (NASH). Arrowhead will receive a $120 million upfront payment and could earn up to $1.1 billion in additional milestone payments and royalties. The agreement allows GSK to develop ARO-HSD globally, except in Greater China, where Arrowhead retains rights. The transaction is expected to close in Q1 2022, pending customary conditions.
